



United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/782,757	02/12/2001	Robert W. Mahley	6510096CIP3	9705
7	590 12/18/2002			
Paula A. Borden			EXAMINER	
BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025			JIANG, SHAOJIA A	
			ART UNIT	PAPER NUMBER
			1617	<u> </u>
			DATE MAILED: 12/18/2002	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N	LA -Booward				
•	Application N .	Applicant(s)				
Office Action Summan	09/782,757	MAHLEY ET AL.				
Office Action Summary	Examiner	Art Unit				
TI MANUALO DATE CHI	Shaojia A. Jiang	1617				
The MAILING DATE of this communication appears n the c ver sh et with the corresp ndence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on 11 S	September 2002 .					
2a) This action is FINAL . 2b) ⊠ Thi	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
	Claim(s) 1-28 is/are pending in the application.					
4a) Of the above claim(s) <u>5-18 and 23-28</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed. 6) Claim(s) <u>1-4 and 19-22</u> is/are rejected.						
7) Claim(s) is/are objected to.						
	8) Claim(s) is/are objected to.					
Application Papers	election requirement.					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accep	oted or b) objected to by the Exa	aminer.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on	_is: a)□ approved b)□ disappr	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4.5	5) Notice of Informat	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/782,757

Art Unit: 1617

DETAILED ACTION

This application is a continuation in part of 09/070675 which is a continuation in part of 08/659785 which Claims Priority from Provisional Application 60/005550.

Election/Restrictions

Applicant's election with traverse of the invention of Group I, Claims 1-4 and 19-22 in Paper No. 8, submitted September 11, 2002 is acknowledged.

Claims 5-18 and 23-28 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-4 and 19-22 are rejected under 35 U.S.C. 102(a) as being anticipated by Scolnick (WO 95/06470, PTO-1449 submitted February 12, 2001).

Scolnick discloses that a HMG-CoA reductase inhibitor, a statin such as lovastatin, simvastatin, pravastatin, and fluvastatin, being an agent that specially reduces apolipoportein E4, is useful in a composition to be administered or a

Application/Control Number: 09/782,757

Art Unit: 1617

pharmaceutical formulation. These statins are known to have molecular weight in a range within the instant claim. See page 3-4, and page 11-14, Example 1-2.

Thus, Scolnick clearly anticipates the claimed invention herein.

Applicant is further requested to note that it is well settled that "intended use" of a composition or product, e.g., "specifically reduces apolipoprotein E4 domain interaction by at least about 10%" in the instant claims, will not further limit claims drawn to a composition or product. See, e.g., *Ex parte Masham*, 2 USPQ2d 1647 (1987) and *In re Hack* 114, USPQ 161.

In view of the rejections to the pending claims set forth above, no claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

S. A. Jiang, Ph.D. Patent Examiner, AU 1617 December 7, 2002

> SREENI PADMANABHAN PRIMARY EXAMINER

12/16/n

Page 3